Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

Here you will find a summary of Ironwood Pharmaceuticals, Inc.'s latest financial information.

Latest Annual Report/10-K

Form	Filing date	View
10-K	Mar 30, 2011	View HTML 0001047469-11-002858.pdf 0001047469-11-002858.rtf 0001047469-11-002858.xls

Latest Proxy Statement

Form	Filing date	View
DEF 14A	Apr 27, 2011	View HTML 0001047469-11-004112.pdf 0001047469-11-004112.rtf 0001047469-11-004112.xls
DEF 14A	Apr 17, 2015	View HTML 0001047469-15-003640.pdf 0001047469-15-003640.rtf 0001047469-15-003640.xls
DEF 14A	Apr 15, 2016	View HTML 0001047469-16-012253.pdf 0001047469-16-012253.rtf 0001047469-16-012253.xls

Ironwood Pharmaceuticals
301 Binney Street
Cambridge, MA 02142

tel 617.621.7722
fax 617.494.0480

ABOUT US

Pharmaceutical
Advisory Committee

Transparency

Patient Assistance

Our MEDICINES

Overview

Discovery of Linaclotide

R&D

COLLABORATE

Accessing Additional Products

Globalization

Investors

NEWS

Join US

LINZESS® is a registered trademark of Ironwood Pharmaceuticals, Inc., ZURAMPIC®, DUZALLO® are registered trademarks of AstraZeneca AB Corporation or its affiliates and are used herein under license.

Market Capitalization (Mil)	$2,801.80
Shares Outstanding (Mil)	$151.94
Shares Outstanding, Average (FY) (Mil)	$148.99
Float (Mil)	$137.20

Financial Information

Latest Earnings Release and 10-Q

Latest Annual Report/10-K

Latest Proxy Statement

Share Related